A major treatment update has arrived for people living with systemic lupus erythematosus (SLE). AstraZeneca announced that the US Food and Drug Administration has approved a new self-injection version of Saphnelo (anifrolumab), giving eligible adult patients a more convenient way to receive therapy at home or with caregiver support.
Previously available as an intravenous infusion administered in clinics, Saphnelo can now be used as a once-weekly autoinjector called the Saphnelo Pen. This approval may improve treatment access, flexibility, and convenience for many patients managing this chronic autoimmune disease.
Saphnelo, also known by its generic name anifrolumab, is a biologic medicine designed to treat moderate to severe systemic lupus erythematosus in adults who are already receiving standard therapy.
It works by blocking type I interferon receptor activity. Interferons are proteins involved in immune system signaling, and overactivation of this pathway has been strongly linked to lupus inflammation and disease progression.
By targeting this pathway, Saphnelo helps reduce disease activity and may lower the need for long-term corticosteroid use.
The newly approved Saphnelo Pen allows patients to self-administer a 120 mg subcutaneous dose once weekly. This means treatment can potentially be taken outside hospital infusion centers, reducing the burden of travel, scheduling appointments, and time spent receiving intravenous therapy.
For many lupus patients, especially those dealing with fatigue, pain, or mobility issues, home administration could make a meaningful difference in quality of life.
The FDA approval was supported by findings from the Phase III TULIP-SC trial, a randomized, placebo-controlled study evaluating subcutaneous anifrolumab in adults aged 18 to 70 with moderate to severe SLE.
Researchers reported that patients receiving Saphnelo experienced a statistically significant and clinically meaningful reduction in lupus disease activity compared with placebo while continuing standard therapy.
Additional reported benefits included:
The safety profile of the injectable form was reported to be consistent with the already known intravenous version.
Systemic lupus erythematosus is a chronic autoimmune disease in which the immune system attacks healthy tissues. It can affect joints, skin, kidneys, heart, lungs, brain, and other organs.
Common lupus symptoms include:
Because lupus symptoms can flare unpredictably, consistent treatment is essential. However, many patients struggle with frequent infusion appointments, transportation barriers, work schedules, and physical exhaustion.
The approval of a self-injectable therapy directly addresses these real-world challenges.
Lupus affects more than 3.4 million people worldwide. It disproportionately impacts women, particularly younger women, and is reported more frequently in Black, Hispanic, and Asian populations.
Traditional lupus treatment often relies on corticosteroids, which can help control inflammation but may lead to long-term complications such as:
Modern lupus care increasingly focuses on achieving remission or low disease activity while minimizing steroid exposure. Therapies like Saphnelo support that treatment strategy.
According to AstraZeneca, more than 40,000 patients globally have been treated with Saphnelo. The intravenous version is already approved in more than 70 countries.
Subcutaneous versions had already received approval in the European Union and Japan before this latest US decision.
If you have lupus and are interested in the Saphnelo Pen, discuss the following with your healthcare provider:
AstraZeneca is also studying anifrolumab in other immune-related diseases, including:
If future studies are successful, the medicine could play a broader role in autoimmune care.
The US approval of the Saphnelo Pen marks an important advancement in lupus treatment. By turning a clinic-based infusion into a self-administered weekly injection, patients may gain greater independence, convenience, and access to targeted therapy.
For those living with systemic lupus erythematosus, innovations that reduce disease burden while fitting into everyday life are especially meaningful. This approval reflects the continued shift toward more patient-centered treatment options in autoimmune medicine.
AstraZeneca announcement.
This article is for informational and educational purposes only. It does not provide medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any medication or lupus treatment plan.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.